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ABSTRACT 
 
DWNN is a novel protein domain first identified in knock-out experiments on CHO 
cells as conferring resistance to cytotoxic T- lymphocyte killing. It is found in all 
eukaryotic genomes so far investigated, with a conserved consensus region of 78 
amino acids. The human form is expressed both as an independent domain of 118 
amino acids, and as part of a larger protein which also includes a zinc finger, a ring 
finger and a domain known from previous studies to bind both of the tumour 
suppressor proteins, p53 and Rb. Structure prediction studies suggest that the domain 
adopts the same 3-dimensional fold as the protein ubiquitin, which is interesting in 
the light of the recently discovered role of ubiquitin- like proteins and Ring fingers in 
the regulation of tumour suppressor proteins. 
 
This work describes the cloning, expression and purification of the DWNN domain 
for structural studies using NMR. Both the 118 amino acid form and a shortened 82 
amino acid form corresponding to the consensus region were successfully expressed 
as fusions with the protein GST. Two different vector systems were used, allowing 
removal of GST using either thrombin or 3C protease. The C-terminal region of the 
118 amino acid protein was found to be susceptible to proteolysis, confirming that 
this region forms an unstructured tail. Samples of the shortened form were 
successfully prepared at concentrations and purity suitable for NMR analysis. 
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CHAPTER 1 
Introduction: The DWNN family and its putative function 
 
1.1 Introduction 
DWNN is a novel gene originally identified in Chinese hamster ovary (CHO) cells. 
CHO cells are functionally haploid, meaning that they are a diploid cell line that 
appear to transcribe only one of the two alleles at a large proportion of loci. 
Retroviral promoter-trap mutagenesis was used to mutagenise the cells by insertion 
into the genome; the mutagenised cells were then screened for susceptibility to CTL 
killing using the lactate-dehydrogenase (LDH) assay. Inverse PCR and RACE PCR 
were used to identify the gene into which the retrovirus was inserted.  
 
Using these methods, a 101bp fragment of hamster genomic DNA was identified. 
BLAST searches results using the fragment yielded a large number of close 
homologues in a wide range of eukaryotic organisms. EST analysis shows that in 
humans the domain is expressed both as a single domain of 13kDa and forms part of 
a 200kDa protein which also includes a zinc finger, a RING finger and a PACT 
domain (unpublished data by Zodwa Dlamini). The PACT domain (p53 associated 
cellular protein-testes derived) is also known as the RBBP6 (Retinoblastoma binding 
protein 6) and interacts with tumour suppressor proteins, retinoblastoma (Rb) and p53 
(Simons et al., 1997). This domain is found as a single copy per genome analysed. 
This domain was named DWNN (Domain With No Name). The consensus region of 
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DWNN is 78 amino acids long. Tertiary structure predictions show that DWNN 
shares the same fold as the protein ubiquitin. Ubiquitin is believed to be involved in 
apoptosis (Macleod, 2000). The findings that the full- length 200kDa protein may 
interact with p53 and Rb raises the possibility that DWNN forms part of essential 
cellular regulation, which may have important implications for the development of 
novel anti-cancer therapies. The work in this study involves generation of 
recombinant 13kDa DWNN, its expression in E.coli and purification for structure 
determination. 
 
1.2 Variable domain organization of DWNN  
DWNN is conserved across eukaryotic organisms, from humans to plants to algae. In 
worms and flies DWNN is found as a 200kDa domain and in algae and ascidians a 
13kDa DWNN has been identified but it is not yet known if it interacts with other 
domains. The full- length 200kDa protein is composed of the DWNN domain, a zinc 
finger, a RING finger and a PACT domain. In organisms such as fungi and plants 
DWNN is associated with the zinc finger and the RING finger and no PACT domain 
as shown in Fig. 1.1. 
 
1.3 DWNN is highly conserved across evolution 
Homologues of DWNN have been found in all eukaryotic organisms for which 
sequence data exist in the database at the NCBI. An alignment of these sequences 
was produced using the Clustal X sequence alignment tool as shown in Fig. 1.2. A 
colour scheme has been used to highlight all the conserved amino acids. The 
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conserved negatively charged amino acids with polar side chains are shown in purple 
(D and E). All the conserved amino acids with non-polar side chains and Cysteine are 
highlighted in blue (M, I, V, L, F and A). The positively charged amino acids with 
polar side chains, K and R are shown in red. Proline is the only cyclic amino acids 
and is highlighted in lime. S, T, N and Q have uncharged polar side chains and are 
shown in green. H and Y, which have polar, aromatic side chains, are highlighted in 
powder blue. Glycine (G), an amino acid that has only hydrogen as its side chain is 
shown in orange in the diagram. This colour scheme makes it easier to identify all the 
conserved amino acids. 
 
From the sequence alignment generated by Clustal X, a phylogenetic tree was 
produced as shown in Fig. 1.3. An alignment is produced to represent the 
evolutionary relationship between species, it is necessary for aligning inference to 
reflect the fact that species are related through an evolutionary tree (Thorne and 
Kishino, 1992). Interesting results were observed from the DWNN phylogenetic tree 
in Fig. 1.3. As expected mouse and human DWNN’s are closely related to each other. 
DWNN sequences from plants (Arabidopsis, tomato, medicago) are closely related as 
they originate from the same branch. 
 
The high level of conservation of the DWNN domain may be an indication that it 
plays an important role in cellular regulation of these organisms. DWNN is also 
found in organisms with minimal genomes such as Encephalitozoa, which has a very 
simple genome as compared to the human genome (Vivarès and Méténier, 2000). The 
  4 
fact that this domain is found in an organism with such a simple genome suggests that 
DWNN may play a very crucial role in eukaryotic cells.  
 
1.4 DWNN and the immune system  
DWNN was first identified in a screen for cells resistant to killing by cytotoxic T-
cells (George, 1995). An implication that can be drawn from this is that DWNN plays 
a role in the killing of cells by cytotoxic T-cells. In order to place this finding into 
context, a brief review of the mammalian immune system is given below. 
 
The mammalian immune system is comprised of T- lymphocytes, B- lymphocytes, 
natural killer (NK) cells, macrophages and antigen-presenting cells (APCs) and their 
various subclasses. Most of these components originate in the bone marrow. The 
responses of the immune system can be divided into two major classes: antibody 
responses and cell-mediated responses. Antibody responses involve the production of 
antibodies that circulate in the bloodstream and permeate other body fluids, where 
they bind specifically to foreign antigens that induce them.  
 
Cell mediated responses involve the production of specialised cells that react with 
foreign antigens on the surface of other host cells thereby getting rid of the infected 
cell. In different situations, the reacting cell secretes chemical signals that activate 
macrophages to destroy the invading microorganisms (Alberts et al., 2000). 
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1.4.1 Components of the immune system 
B lymphocytes 
B-cells produce cell membrane receptors that are also known as antibodies and have 
single antigen specificity. These lymphocytes are selected in the bone marrow and 
when matured they leave for secondary lymphoid organs such as the spleen, lymph 
nodes and the gut associated lymphoid tissue. When B cells are activated by antigen, 
they undergo a second round of selection in the follicles of secondary lymphoid 
organs after which they mature into plasma cells that produce and secrete antigen-
specific antibodies. These antibodies then re-circulate to the bone marrow. This re-
circulation ensures that the appropriate B lymphocytes come into contact with 
antigens (Krammer, 2000).  
 
T lymphocytes 
Pre-T lymphocytes move from the bone marrow into the thymus. T cells are selected 
in the thymus on the basis of the affinities of their T-cell antigen receptors (TCRs) for 
self-major histocompatibility (MHC) antigens. Two classes of the MHC antigen are 
present and are known as MHC class I antigen and MHC class II antigen. MHC I 
antigen sample peptides are from foreign proteins and MHC II antigens sample 
peptides are from self-proteins. Three key steps involved in antigen processing in 
association with MHC class I have been identified, cytosolic peptide generation with 
the help of the proteasome, peptide transport into the endoplasmic reticulum and 
peptide assembly with class I molecules (van Endert, 1999).  
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T-cells with high affinity for self-MHC molecules are eliminated to prevent 
autoimmunity. T-cells that interact with MHC class II molecules develop into cells 
that possess CD 4 antigens on their surface and T-cells with high affinity for MHC 
class I possess CD 8 antigens on their surface. Only mature T-cells with functional 
TRC leave thymus for secondary lymphoid organs. Mature CD 4+ T-cells develop 
into T-helper 1 cells that secrete cytokines, which regulate cellular immune response 
and T-helper 2 cells that secrete cytokines, which regulate antibody response. Mature 
CD 8+ T-cells become cytotoxic killer cells in the presence of infectious agent and 
APCs present antigenic peptides to T-cells. Antigen-MHC complexes stimulate APS 
surface molecules and cytokines to drive T cell into clonal expansion. These T-cells 
then send a message to the T-cells or B-cells to regulate their responses. The immune 
response then undergoes a down-phase. Most lymphocytes are eliminated by 
apoptosis and the few cells that survive will join the pool of memory cells (Krammer, 
2000). 
 
1.4.2 CTL pathways 
Cytotoxic lymphocytes include activated CD4+ and CD8+ lymphocytes, natural killer 
(NK) cells, and lymphokine activated killer (LAK) cells (Thomas et al., 2000). These 
cells play a vital role in the functioning of host immune system’s response against 
viral infections and tumours (McMichael, 1992). The target cells for CTLs display 
viral or tumour peptides that are bound to MHC-1 glycoprotein on their plasma 
membrane (Townsend and Bodmer, 1989). CTLs morphological changes and motility 
play an important role in their functioning (Waters et al., 1996). Activated CTLs are 
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highly motile and must move through all tissues of the organism (Hahn et al., 1994). 
Cytotoxic T lymphocytes induce apoptosis in two distinct pathways to lyse target 
cells (Atkinson et al., 1998 and Beresford et al., 1998). These two pathways are the 
Fas mediated pathway and perforin pathway (Barry et al., 2000).  
 
The Fas pathway involves binding of Fas death receptor on the surface of target cells 
(Peter and Krammer, 1998). The interaction of Fas receptor/ligand plays a role in the 
recruitment of caspase 8 through the adapter molecule FADD (Fas-associated death 
domain) also known as MORT1 (Boldin et al., 1996). Caspase 8 gets activated 
autocatalytically and then activates downstream caspases (Barry et al., 2000), after-
which apoptosis of target cells resumes. 
 
The Perforin pathway involves exocytosis of cytolytic granules from CTLs (Barry et 
al., 2000). These granules are made up of a variety of proteins required for apoptosis 
of the target cell (Griffiths and Argon, 1995). One of these proteins is a pore-forming 
protein known as perforin, which is thought to facilitate the entry of other proteins 
involved in this pathway and a family of serine proteases known as granzymes (Barry 
et al., 2000). Studies have shown that the substrates for these proteases are the 
caspases; for example, the substrate for granzyme B was found to be caspase 3 
(Darmon et al., 1995). Other caspases have been shown to be granzyme substrates in 
vitro suggesting that granzyme B induces apoptosis of the target cell by triggering the 
activation of caspases (Barry et al., 2000). However, only caspase 3 and 8 have been 
shown to be substrates for granzyme in vivo (Atkinson et al., 1998; Yang et al., 1998 
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and Medema et al., 1997). These studies prove the importance of caspase 8 in both 
the Fas-mediated cell death and perforin pathway. 
 
1.4.3 Identification of DWNN 
CTL killing plays a role in the removal of viral particles, damaged cells and 
cancerous cells. These CHO cells were sensitised to lysis by HA-specific KK 
restricted CTL, by the transfection of L-HA and MHC class I KK. As mentioned 
previously, these cells are functionally haploid and thus creating suitable cell lines for 
mutagenesis as integration event may lead to loss of gene function. 
 
Insertional mutagenesis was performed by using a defective promoter-trap retrovirus. 
The retrovirus is inserted downstream of an active promoter of the host gene thereby 
disrupting the expression of that gene. The promoter-trap retrovirus is characterised 
by the presence of a hygromycin resistance gene which is expressed once the 
retrovirus integrates downstream of an active cellular promoter. If the disrupted gene 
is involved in the CTL pathway then the cells should be resistant to CTL killing.  
 
The mutagenised CHO cells were subjected to HA-specific CTL lysis. More than 100 
CTL resistant cell lines were generated using promoter-trap mutagenesis and 3 cell 
lines were shown to be totally resistant to CTL killing (George, 1995). Inverse PCR 
and rapid amplification of cDNA ends (RACE) PCR were utilised to identify the 
sequence of the inactivated gene from a number of the CTL resistant cell lines. One 
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of the cells yielded a fragment that when BLASTed against the genomic database, it 
was found to be novel (Pretorius, unpublished data 1998) 
 
1.5 DWNN and Apoptosis  
A study showing that there might be a relationship between DWNN and apoptosis 
was conducted and is discussed in this section. Since DWNN was initially identified 
in a screen for cells resistant to CTL killing and CTL killing has two pathways of 
which one leads to apoptosis, this raised the possibility that DWNN plays a role in 
apoptosis. 
 
1.5.1 Apoptosis 
Apoptosis is a fundamental process, also known as programmed cell death that is 
essential for cellular development and tissue homeostasis. Changes in this process 
may lead to many pathological conditions including viral infection, autoimmune 
disorder and cancer. The human body is composed of ~ 1014 cells, each of which has 
the ability to commit suicide by apoptosis (Nicholson, 2000), thus this fact shows the 
importance of apoptosis in development. During development of organisms, 
apoptosis is induced in supernumerary, misplaced or damaged cells during the 
construction, maintenance and repair of tissues (Meier et al., 2000). When this 
process is compromised inappropriate cell death and disease pathogenesis can result. 
Apoptosis is characterised by condensation and fragmentation of the chromatin 
network, compaction of cytoplasmic organelles, dilation of the endoplasmic 
reticulum, a decrease in cell volume and changes in the plasma membrane resulting 
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in the recognition and phagocytosis of apoptotic cells (Cohen, 1997; Arends and 
Wyllie, 1991). The apoptotic cells are then removed by phagocytosis.  
 
It has been shown that cells dying from apoptosis undergo morphological features 
that are different from cells that die through pathology and necrosis. These 
morphological changes include cell shrinkage, the blebbing of plasma membranes 
and nuclear condensation (Sakahira et al., 1998). This led to the hypothesis that a 
common conserved endogenous cell death program is responsible for apoptosis. 
These common morphological changes were caused by cysteine proteases that are 
activated specifically in apoptotic cells. These proteases are homologous to one 
another and form part of a large family known as the caspases (Alnemri et al., 1996). 
The caspases are well conserved throughout species ranging from humans to 
nematodes. Since caspases lead to a visible change that characterise apoptosis, they 
are thought to be the central executioners of the apoptotic pathway (Hengartner, 
2000). Some caspases are cleaved and activated by other caspases. It is thought that 
the initiator caspases get activated when they are isolated and combined by bridging 
or regulatory factors. Caspase-mediated cell death is suppressed by Bcl-2, the origin 
of a family of proteins that suppress apoptosis. (Chau et al., 2000). 
 
There are many pathways involved in apoptosis but only the Fas pathway is common 
to both apoptosis and CTL killing since DWNN has been shown to be involved in 
CTL killing and apoptosis (see below). A possible scenario is that DWNN might play 
a role in the Fas pathway. Fas pathway is discussed in section 1.4.2. 
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1.5.2 Apoptosis resistance screens and DWNN 
Apoptosis was induced in the mutagenised cell lines generated as described in section 
1.4.3 using staurosporine. The cells did not die, indicating that they were resistant to 
staurosporine (unpublished data). These results suggested that DWNN could play an 
important role in apoptosis. If so, DWNN may be an important anti-cancer therapy 
candidate because cancer frequently develops when apoptosis fails to occur. 
 
1.6 DWNN and Cancer 
The full protein of which the DWNN domain forms the N-terminal part has 
previously been shown to interact with both p53 and Rb (Simons et al., 1997). Since 
p53 and Rb are both known to play vital roles in the control of cancer, this suggests a 
possible role for DWNN in the regulation of cancer. In order to place these 
hypotheses into context, a brief review of tumour suppressor genes is presented 
below. 
 
1.6.1 Tumour suppressor genes 
Tumour suppressor genes are required to keep cell growth under control. They are 
responsible for example, for controlling the cell cycle, DNA replication and cell 
division. When these genes fail, uncontrolled cell growth will occur which is a 
characteristic of cancerous cells. Tumours develop when tumour suppressor genes do 
not function properly. The tumour suppressor genes that are of importance in this 
study are p53 and Rb. 
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p53 
p53 induces apoptosis and it is known to prevent genomic instability as well as being 
involved in growth arrest (Macleod, 2000). It has been found that p53 does not 
function properly in approximately half of the tumours (Vogelstein et al., 2000). It is 
also known that p53 has a short half- life in cultured cells, and that it accumulates 
after cellular exposure to DNA-damaging agents (Hupp et al., 2000), which suggests 
that there has to be a p53 regulator which is responsible for p53 degradation.  
 
Mdm2 
p53 interacts with murine double minute clone 2 (Mdm2), which binds the N-
terminus of p53 and is one of the most important p53 regulators. The interaction of 
Mdm2 with p53 results in the inhibition of the ability of p53 to act as a transcription 
factor and also targets p53 for degradation through ubiquitin-dependent proteolysis 
(Zhang et al., 1998). A negative feedback loop is thus formed because Mdm2 causes 
p53 to activate a component of its own degradation (Haupt et al., 1995 and Chao et 
al., 2000). Mdm2 has been shown to act as an E3-ubiquitin ligase and this activity 
plays a role in the targeting of p53 for ubiquitin-dependent degradation. E3 ligases 
are essential in ubiquitin conjugation, which is a process that leads to the covalent 
modification of proteins with ubiquitin and their subsequent degradation by the 
proteosome. Mutations in the RING finger that is present in Mdm2 and most E3 
ligases results in the stabilisation of Mdm2 and loss of the ability to degrade p53 as it 
can also ubiquitinate itself. The E3 activity of Mdm2 is dependent on zinc and 
multiple metal co-ordinating ring residues (Lorick et al 1999). The ability of Mdm2 
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to act as ubiquitin- ligase might serve to target p53 directly to proteosome but 
ubiquitination of p53 may have other effects on the regulation of p53 stability and  
activation (Macleod, 2000; Kubbutat and Vousden, 1998). 
 
Rb  
Rb interacts with Mdm2 and thereby promotes p53 activity by blocking its Mdm2-
mediated degradation. Unlike most tumour suppressor genes, Rb acts to prevent 
apoptosis through induction of the pro-apoptotic Bax gene and also through an 
uncharacterised mechanism requiring Apaf-1 and caspase 9. Rb is a critical negative 
regulator of the cell cycle and by linking loss of Rb to the induction of apoptosis, the 
cell prevents deregulated proliferation and tumour formation (Macleod, 2000). Rb 
suppresses cell proliferation and is mutated in various types of human cancer 
(Weinberg, 1992).  
 
1.6.2 Interactions between DWNN and tumour suppressors  
DWNN domain forms part of a large protein containing the PACT domain, which is 
known to interact with Rb and p53. The significance of the interaction of the PACT 
domain and the Rb is not yet fully understood (Sakai et al., 1995). It also contains a 
RING finger domain, which raises the possibility that it may play a role in the 
ubiquitin-dependent regulation of Rb and DWNN.  
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1.7 Ubiquitin and DWNN 
Modelling studies predict that DWNN is likely to adopt the same 3D fold as ubiquitin 
(Pugh and Jonas, unpublished). In the context of recent findings linking ubiquitin and 
ubiquitin- like proteins to the regulation of both apoptosis and cancer, a possible role 
for DWNN in these processes is suggested. 
 
1.7.1 Ubiquitin 
Ubiquitin is a 76 amino acid protein found in all eukaryotic cells either independent 
or bound covalently to cellular proteins and highly conserved in evolution 
(Ciechanover, 1994 and Yeh et al., 2000). Ubiquitin tags protein for degradation by 
the proteosome or through the endocytic route. Conjugation of ubiquitin to other 
proteins includes the formation of an isopeptide bond between the C-terminal glycine 
residue of ubiquitin and the e-amino group of a lysine residue of an acceptor protein. 
It is thought that all known functions of ubiquitin are carried out through this 
reaction.  
 
Ubiquitin binds to its substrates through an enzymatic cascade, involving ubiquitin-
activating (E1) enzyme, ubiquitin-conjugating (E2) enzyme and in some cases 
ubiquitin-protein ligases (E3) (Tyers and Jorgensen 2000; Hershko and Ciechanover 
1998). The E1 enzyme hydrolyses ATP and through an E1-bound ubiquitinyl 
adenylate intermediate, forms a high-energy thioester between a cysteine of its active 
site and the C-terminus of ubiquitin. Ubiquitin is then moved on to E2 enzyme to 
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form thioester- linked complexes in the similar manner as with E1 enzyme. At the 
end, ubiquitin is covalently bound to the substrate protein by the E2 or by the E3 
enzyme, which may possess substrate-binding properties (Liakopoulos et al., 1998 
and Scheffner et al., 1995). The principal regulatory step of substrate recognition is 
carried out via the E3 ubiquitin ligases. The recognition of target proteins as 
substrates appears to involve protein-protein interactions with specific E3s but the 
role of E2 enzyme in substrate recognition has not yet been established (Kumar et al., 
1997). 
 
1.7.2 Ubiquitin-like proteins  
Ubiquitin- like proteins include proteins that function in a similar manner as ubiquitin 
and those that possess ubiquitin domains but are unrelated in sequence with ubiquitin 
(Jentsch and Pyrowolakis, 2000). The list of these proteins is expanding but only the 
well-characterized proteins will be mentioned in this section. 
 
SUMO-1 (small ubiquitin-related modifier)/sentrin-1 is a small ubiquitin- like protein 
found in higher eukaryotic cells, which determines the sub-cellular localisation of 
proteins. SUMO has recently been shown to interact and activate p53 although the 
relevance of this has not yet been discovered (Lohrum and Vousden, 2000 and Hupp 
et al., 2000). The NMR structure of SUMO-1/sentrin-1 suggests that it contains a 
ubiquitin-homology domain and a very flexible N-terminus that protrudes from an 
ubiquitin- like core (Bayer et al., 1998). This protein is only 18% identical in 
sequence with ubiquitin. Although many SUMO-1/sentrin-1 targets have been 
  16 
identified, the consequences of SUMO/sentrin-1 modification are not yet known. 
SUMO modification does not appear to lead to protein degradation in the same 
manner as the ubiquitin pathway but has been shown in some instances to be linked 
to the ubiquitin system (Liakopoulos et al., 1998). The sentrinisation pathway 
deviates from the ubiquitination pathway at an early stage (Yeh et al., 2000). NEDD8 
(Neural precursor cell-Expressed Developmentally Down regulated protein 8) is a 
protein that shares 60% identity and 80% similarity with ubiquitin and was firstly 
found to be a novel mRNA highly enriched in foetal mouse brain (Kumar et al., 
1992). The major substrate for this protein is Cdc53, which is a yeast cullin (Yeh et 
al., 2000). 
 
1.7.3 Tertiary structure prediction of DWNN 
Tertiary structure prediction studies were performed using Modeller, a computer 
program that models the 3D structures of proteins. Tertiary structure prediction 
studies showed that DWNN’s fold is comparable to that of ubiquitin, see Fig. 1.4. 
The similarity of amino acid sequences of two different proteins is not related to the 
function of those proteins but if they have a similar fold they are more likely to 
perform similar functions. 
 
These results reveal that both DWNN and ubiquitin possess five b-sheets and one 
a-helix each that fold in the similar manner on both proteins. Three-dimensional 
studies are required in this study to confirm these findings. It has been found that 
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ubiquitin ligases, which bind ubiquitin to proteins for degradation have RING fingers 
(Tyers and Jorgensen, 2000). Human 200kDa DWNN protein also has a RING finger 
and led to the hypothesis that DWNN might be one of or related to ubiquitin ligases 
but more investigation is required to confirm this. 
 
1.8 Protein structure determination by NMR 
Proteins play an important role in cells, as the morphology, function and activities of 
the cell depend on the proteins they express. The key to understanding how different 
proteins function lies in an understanding of the molecular structure. The overall aim 
of this research is the determination of the structure of DWNN domains; this thesis 
describes the preparation of samples of human DWNN suitable for structural analysis 
by NMR, as well as preliminary NMR analysis. 
 
Nuclear Magnetic Resonance spectroscopy (NMR) was introduced as a second 
structure determination method after X-ray crystallography, which required 
crystallisation of proteins prior to collection of data. Some proteins do not crystallise 
well and even when they do crystals may diffract poorly or there may be difficulties 
in solving the phase problem (Clore and Gronenborn, 1991). For NMR studies, the 
protein in question should be soluble and must be able to be concentrated to at least 1 
mM in a volume of 0.5ml. The upper molecular weight limit of a protein to be 
studied using NMR is ~ 50 -60kDa for the applicability of current solution NMR 
technology. 
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1.8.1 1-D NMR 
This NMR technique is based on the fact that some nuclear isotopes, including 1H, 
13C and 15N, have magnetic properties. When a molecule containing such isotopes is 
placed in a magnetic field of strength B0, the nuclei precess about the direction of the 
field, giving rise to a fluctuating magnetic field. The fluctuating field is observed, 
amplified and Fourier transformed to give a 1-D spectrum, as shown in Fig. 1.5. Each 
peak (or resonance) in this spectrum corresponds to a particular proton in the protein. 
The amide protons, which are on the left hand side of the spectrum in Fig. 1.5, 
precess at a different frequency from the aromatic protons, near the centre of the 
spectrum, and the aliphatic protons at the right hand side, due to the different 
chemical environment of the protein backbone, the rings or the hydrocarbon side 
chains. The difference in precession frequency between protons in different chemical 
environments is known as “chemical shift”, and is represented by the Greek symbol 
d.  Chemical shift is a consequence of protein folding and a broad spread of d is a 
good indicator that a protein is well folded; the addition of chemical denaturants such 
as urea and guanidinium causes the peaks to collapse in towards the middle of the 
spectrum.  
 
d  is proportional to the magnetic field B0, which means that spectra from 
spectrometers with different magnetic field strengths cannot be superimposed. To get 
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around this problem, 1D spectra are plotted in dimensionless units defined relative to 
an arbitrarily chosen reference frequency d0, as follows: 
(d0-d)/ (d0 x 106) 
Because of the inclusion of the factor of 106, these units are commonly referred to as 
“parts per million”, or “ppm”. Since d0 and d are both proportional to the strength of 
the magnetic field, chemical shifts expressed in terms of ppm are independent of the 
magnetic field strength, and therefore the same for all spectrometers. Proton 
resonances typically fall in the range 0 –10ppm. 
 
Water is used as a solvent for most biological molecules such as proteins. The 
chemical shift of water protons lies in the centre of the 1D spectrum of the proteins at 
4.7ppm. Given the molarity of the water protons is 110M and the maximum molarity 
of a protein is ~ 10mM, the water resonance would ordinarily be expected to swamp 
protein resonances. Sophisticated “water-suppression” techniques therefore have to 
be used to reduce the magnitude of the water resonance relative to the protein 
resonances. Alternatively H2O can be replaced as solvent by D2O, deuterium oxide, 
which is chemically identical to water, but has the advantage that the deuterons do 
not have a magnetic signal in the same range as proteins. 
 
1.9 MALDI-TOF mass spectrometry 
Matrix Assisted Laser Desorption/Ionization – Time Of Flight (MALDI-TOF) mass 
spectrometry was used in this study to confirm the sizes of recombinant protein. This 
  20 
technology is appropriate for bio-molecules due to the gentle ionisation method used. 
A laser is used to ionize the sample, which has been pre-absorbed out of a readily 
vaporizable matrix (van Baar, 2000). Once the sample molecule has been vaporised 
and ionised they are electrostatically transferred into a time-of-flight (TOF) 
spectrometer where they are separated from the matrix ions and analysed, based on 
their mass-to-charge (m/z) ratios (Lennon and MALDI basics). In this study, MALDI-
TOF was used to determine the molecular weight of DWNN. 
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CHAPTER 2 
Materials and Methods 
 
2.1 Materials and Suppliers  
40% 37.5:1 acrylamide:bis-acrylamide   Promega  
Ampicillin       Roche 
Boric acid        Saarchem UNIV AR  
Calcium chloride      BDH anala R  
Cesium chloride      Roche 
Chloroform       BDH anala R 
Coomasie Brilliant Blue R 250    Sigma 
DTT (Dithiothreitol)      Roche 
EDTA        Saarchem UNIV AR  
Ethanol       BDH anala R  
Ethidium bromide      Sigma 
Glucose       Saarchem UNIV AR 
Glycine       Saarchem UNIV AR 
IPTG        Promega 
Mops        Roche 
PBS (Phosphate-buffered saline) tablets   Life Technologies 
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PEG 8000       Sigma 
PMSF        Sigma 
Sodium hydroxide      Saarchem UNIV AR 
Sodium dodecyl sulfate     Roche  
TEMED       Promega 
Triton X-100 Riedel-De Haën Ag 
Seelze-Hannover 
All other chemicals (powder compounds) were from MERCK and the rest of organic 
compounds were from Saarchem UNIV AR 
 
2.2 Solutions  
1xTBE 89mM Tris, 89mM Boric acid, 3mM EDTA pH 
8 
2x SDS-PAGE Sample Buffer 0.125M Tris-HCl pH 6.8, 4% SDS, 20% 
glycerol, 10% 2-mercaptoethanol 
APS     10% ammonium persulphate 
SDS-PAGE Destaining Solution  50% methanol, 10% acetic acid, 40% dH2O 
SDS-PAGE Drying Solution  5% glycerol, 30% ethanol, 65% dH2O 
GTE 50mM Tris-HCl pH 8, 10mM EDTA, 1% 
glucose 
Initiator    10% ammonium persulphate 
  23 
L-agar 0.1% meat extract, 0.5% peptone, 0.2% yeast 
extract, 0.8M NaCl, 1.5% agar 
LB     1% bacto-tryptone, 0.5% yeast extract,  
10g l-1 NaCl 
NaOH/SDS    200mM NaOH, 1% SDS 
PBS     Phosphate-buffered saline 
Phenol/chloroform   1:1 phenol: chloroform (v/v) 
PMSF Stock    10mM PMSF, dissolved in isopropanol 
SDS-PAGE Running Gel Buffer 1.5M Tris-HCl pH 8.8 
Salt-saturated propan-2-ol  3M NaCl dissolved in propan-2-ol 
SDS-PAGE Stacking Gel Buffer 0.5M Tris-HCl pH 6.8 
Coomassie Stain 0.125% Coomasie stock, 50% methanol,  
10% acetic acid, 39.875% dH2O 
Commassie Stain Stock  1% Coomassie Blue R-250 
SDS-PAGE Tank Buffer 0.025M Tris-HCl pH 8.3, 0.192M glycine,  
0.1% SDS  
TBS     50mM Tris-HCl pH 8.5, 150mM NaCl 
TE     10mM Tris-HCl pH 7.4, 1mM EDTA 
Tfb 1 30mM KOAc, 50mM MnCl2, 100mM KCl,  
10mM CaCl2, 15% glycerol 
Tfb 2 10mM Na-MOPS, pH 7, 75mM CaCl2, 10mM 
KCl, 15% glycerol 
TTBS     TBS with 0.1% (v/v) Triton X-100 
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TYM 2% bacto-tryptone, 0.5% yeast extract, 0.1M 
NaCl, 10mM MgCl2  
All solutions were made up in deionized water (dH2O) 
 
2.3 Bacterial cultures 
Unless stated otherwise, bacteria were grown in LB. Antib iotics and supplements 
were added as specified in individual protocols. 
 
2.3.1 Bacterial strains used 
E. coli MC1061: F- araD139 ? (ara-leu)7696 galE15 galK16 ? (lac)X74 rpsL 
(Strr) hsdR2 (rk-mk+) mcrA mcrB1 
E. coli BL 21 Gold  F- ompT hsdS(rB- mB-) dcm+ Tetr gal endA Hte 
 
2.3.2 Selection 
In all experiments using E.coli containing ampR plasmids, transformed cells were 
plated on L-agar with ampicillin at a concentration 100mg.ml-1. 
 
2.3.3 Storage of bacterial strains  
Bacterial strains were stored as glycerol stocks. Overnight cultures were diluted by 
addition of an equal volume of 30% glycerol, vortexed and stored at –700C. 
 
2.4 pGEX expression vectors  
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pGEX vector is an expression vector that forms the basis of the GST (glutathione-S-
transferase) expression system. There are three major types of pGEX plasmid (T, P 
and X) which differ in the protease cleavage site (Thrombin, PreScission or Factor 
Xa) they possess upstream the poly- linker region. The genes are expressed as fusion 
proteins with the 26kDa GST protein from Schistosoma japonicum. The pGEX 
plasmids produce high- level of intracellular expression driven by a tac promoter and 
induced with IPTG. The expression vectors pGEX-4T-3 and pGEX-6P-2 were used 
in this study. pGEX-4T-3 contains a thrombin recognition site and pGEX-6P-2 
contains the PreScission recognition site.  
 
2.5 Preparation of E. coli competent cells for transformation 
a) A single colony was taken from a freshly streaked nutrient agar plate and 
transferred to 20ml of TYM and grown with vigorous shaking at 370C to an OD550 = 
0.2. The cells were then transferred to 100ml TYM and grown to OD550 = 0.2. The 
culture was transferred to 400ml TYM and grown under the same conditions to OD550 
= 0.5. 
b) The cells were rapidly chilled at 00C and pelleted by centrifugation at 3000rpm for 
10min at 40C. 
c) The bacterial pellet was re-suspended in 250ml of cold Tfb 1 and incubated at 40C 
for 30min. The cells were recovered by centrifugation at 3000rpm for 10min at 40C. 
The pellet was gently re-suspended in 50ml Tfb 2, divided into 500ml aliquots and 
frozen in liquid nitrogen before long-term storage at –700C. This method yielded 
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transformation efficiencies of 1 - 5 x 107 transformants per mg super-coiled DNA. 
 
2.6 Transformation of E. coli 
a) Competent E. coli strains were transformed with super-coiled DNA according to 
the following protocol: 
b) Frozen competent cells were thawed on ice  
c) 100ml of cells were added to 1-10ng of DNA and incubated on ice for 30 min 
d) The mixture was heat shocked at 370C for 5min. 1ml of LB was added to the 
transformation mix and the cells incubated for a further 30min, to allow expression of 
the antibiotic resistance markers. Cells were plated on appropriate antibiotic- 
containing plates and incubated overnight at 370C. 
 
2.7 Large-scale preparation of plasmid DNA  
a) A 500ml – 1000ml culture of plasmid-containing E. coli in the presence of 
100ml.ml-1 ampicillin was grown overnight with shaking at 370C. 
b) The bacteria were pelleted by centrifugation at 5000rpm for 10min at 40C. 
c) The pellet was re-suspended in 4ml GTE and incubated on ice for 5min. The cells 
were lysed by the addition of 8ml NaOH/SDS with gentle swirling and incubated on 
ice for 5min. 6ml of pre-chilled 3:5M KOAc was added and mixed gently to 
neutralise the alkali, and the mixture was incubated on ice for 5min. 
d) The precipitate of cell debris, chromosomal DNA and SDS was removed by 
centrifugation at 10 000rpm for 15min at 40C. The supernatant was filtered through 
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glass wool to remove particulate material and the nucleic acids precipitated by the 
addition of 1 volume propan-2-ol, followed by incubation at –200C for 30min. 
e) The precipitate was pelleted by centrifugation at 10 000rpm 15min at 40C. Plasmid 
DNA was separated from RNA by either polyethylene glycol (PEG) precipitation or 
double CsCl/ethidium bromide fractionation. 
 
2.7.1 PEG precipitation 
(i) The pellet was re-suspended in 5ml TE. 100mg/ml of RNase was added and 
incubated at 370C for 60min. 
(ii) The RNase was removed by a single extraction with 1:1 phenol: chloroform. 
The supernatant was transferred to a clean tube, 0.3M NaOAc was added and 
the nucleic acids precipitated by the addition of 2.5 volumes of ethanol and 
incubated at –200C for 30min. 
(iii) The pellet was collected by centrifugation at 10 000rpm for 10min at 40C and 
re-suspended in 2ml 2.5M NaCl by vortexing. 2ml 13% polythylene glycol 
8,000 was added to precipitate the DNA. The mixture was vortexed 
thoroughly and incubated on ice for 30min. 
(iv) The precipitate was pelleted at 10 000rpm for 10min at 40C. The pellet was 
washed with 70% ethanol and re-suspended in 100ml TE. 
 
2.7.2 Double CsCl/ethidium bromide fractionation 
This method was used to produce high quality plasmid DNA 
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(i) The propan-2-ol pellet was re-suspended in 4.5ml TE, 5.75g CsCl and 400ml 
of 10mg/ml ethidium bromide was added and the mixture was vortexed. 
(ii) 1.61g/ml density of the mixture was required. TE and saturated CsCl were 
used to decrease and increase the density respectively until the required 
density was achieved. The mixture was centrifuged at 12 000g for 10min at 
200C. 
(iii) The solution was transferred to quickseal ultracentrifuge tubes and was 
centrifuged at 55 000rpm for 16hrs at 200C. The plasmid DNA was recovered 
using a syringe and extracted 3 times with salt-saturated propan-2-ol to 
remove ethidium bromide. 
(iv) 2 volumes of water were added and the solution thoroughly mixed to dissolve 
salts, 1volume propan-2-ol was added and the solution was mixed and 
incubated on ice for 10min to precipitate DNA.  
(v) The mixture was centrifuged at 10 000rpm for 15min and the pellet was 
washed with 70% ethanol. The pellet was re-suspended in 100ml TE 
 
DNA purified by both methods was found to be free of contaminating chromosomal 
DNA and RNA when examined by agarose gel electrophoresis. Plasmid DNA was 
stored at 40C (short term) or –200C (long term). 
 
2.8 Small scale preparation of plasmid DNA. 
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In order to analyse large numbers of transformants, plasmid DNA was isolated from 
overnight cultures of E. coli picked from single colonies. This method yielded DNA 
of sufficient quantity and purity to perform restriction analysis. 
a) 1.5ml saturated overnight cultures of plasmid-containing E. coli were grown 
in LB containing 100mg ml-1 ampicillin.  
b) The bacteria were pelleted in a microfuge at 6000rpm for 10min and re-
suspended in 200ml GTE after which the mixture was incubated at room 
temperature for 5min. 400ml NaOH/SDS was added to lyse the cells and 
incubated at room temperature for 5min. The mixture was neutralised by the 
addition of 300ml 3:5 KOAc, mixed gently and incubated at room temperature 
for 5min. 
c) The precipitate was pelleted at 13 000rpm for 15min. 800ml of the supernatant 
was added to 600ml propan-2-ol in a fresh tube and incubated at –200C for 
30min. 
d) The precipitate of nucleic acid was pelleted at 13 000rpm for 10min, washed 
with 70% ethanol and re-suspended in 500ml TE. 
e) 100mg/ml RNase was added and incubated at 370C for 1hr and RNase was 
removed by single extraction with 1:1 phenol: chloroform. 
f) The DNA was recovered by ethanol precipitation in which 1/10 volume of 
3M NaOAc and 2.5 volumes of ethanol were added to precipitate the DNA 
and the pellet was once again washed with 70% ethanol and re-suspended in 
50ml TE. 
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2.9 Restriction enzyme digests 
Restriction enzymes were used according to the manufacturers’ instructions. Where 
multiple digests were to be performed, the buffer conditions were selected to be 
compatible with both enzymes. Where this was not possible, after the completion of 
the first digest, the enzyme was removed by phenol:chloroform extraction and 
ethanol precipitation. The buffer conditions were adjusted accordingly and the second 
digest performed. All restriction enzymes used in this study were purchased from 
Roche. The PCR product was cut out of 1% agarose gel, recovered using BIO 101 
gene-clean kit (Southern Cross Biotechnology) and re-suspended in 10ml of 1 x TE 
before restriction digest. 
 
2.9.1 Shrimp alkaline phosphatase treatment of restriction digested DNA 
200mg/ml of DNA was digested with Bam HI (10U/ml) and Xho I and included shrimp 
alkaline phosphatase and 0.5ml BSA in the digestion mixture. The total volume of the 
digestion was 50ml. Restriction enzymes and BSA used in this experiment were from 
New England Biolabs. The digestion mixture was incubated at 370C for 3hrs  
 
2.10 Ligations of insert to vector 
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Ligations were carried out in 300mM Tri-Cl (pH 7.8), 100mM MgCl2, 100mM DTT 
and 10mM ATP, using 3U DNA ligase and less than 10ng DNA (i.e. vector and 
insert) at room temperature for 16hrs. T4 DNA ligase kit from Promega was used in 
this study. Ligation reactions were then transformed into competent E. coli MC 1061 
cells and 100ml of the ligation reaction was plated on LB plates with 100mg/ml 
ampicillin, in duplicate. 
 
2.11 Agarose gel electrophoresis of DNA 
2.11.1 Gel preparation and electrophoresis 
Gels were prepared by boiling the appropriate mass of agarose in 1xTBE, cooling to 
500C, adding ethidium bromide to 1mg ml-1 and then setting this in the chosen gel 
former. TBE was used in the preparation and electrophoresis of all gels except when 
gene cleaning was to be conducted. 
 
2.11.2 Sample preparation. 
Approximately 1mg DNA in 5 – 20ml was mixed with 0.5 volume of DNA loading 
buffer and loaded into the gel. 
 
2.11.3 Detection of DNA 
Ethidium bromide intercalates DNA, and in this state fluoresces when illuminated by 
ultraviolet (UV) light. For analytical purposes, DNA was visualised by illuminating 
the gel with short wave UV light on a trans- illuminator. When DNA was to be 
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recovered from the gel, a hand-held long wavelength lamp was used to avoid damage 
of the DNA. 
 
 
2.12 Amplification of DNA by the polymerase chain reaction (PCR) 
The two different PCR kits used in this study are discussed below. 
Takara Taq PCR 
1U of Takara Taq polymerase per PCR reaction was used, 2.5mM MgCl2, 10ng of 
template, 50mM dNTPs and 25pmol of each primer were used in each reaction. A 
standard buffer of 20mM Tris-HCl pH 8, 100mM KCl, 0.1mM DTT, 0.5% Tween 20, 
0.5% Nonidet P-40, 50% Glycerol was used. The reaction mix was incubated at 950C, 
2min followed by 940C, 30sec; 640C, 30sec; 720C, 1min for 35 cycles followed by an 
incubation at 720C for 10min.  
Mastermix PCR 
A master mix from Promega was used in PCR reactions. PCR Master Mix(a,b,c) 
includes Nuclease-Free Water and PCR Master Mix. PCR Master Mix is a premixed, 
ready-to-use solution containing Taq DNA Polymerase, dNTPs, MgCl2 and reaction 
buffers at optimal concentrations. PCR reactions included addition of 10ng DWNN 
encoding cDNA, 1ml of 10pmol forward and reverse primer, an extra 2mM MgCl2 
and 18ml nuclease free dH2O from Promega mastermix. 
 
2.13 Colony PCR  
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The Colony PCR technique was used to screen for possible clones and carried out 
using a protocol modified from Gussow and Clackson 1989. The colonies to be 
screened were re-suspended in 10ml of dH2O. 11 colonies from ligation plate 1 and 1 
colony from ligation plate 2 were selected using sterile toothpicks and re-suspended 
in 10ml of dH2O. 1ml of the re-suspended colony from each tube was used in each 
colony PCR reaction. The colony PCR was set-up in exactly the same way as the 
PCR technique presented in Section 3.2., except that the re-suspended colonies were 
used instead of template DNA. A negative control that contained dH2O instead of 
DNA was prepared to give an indication of contamination occurrence, which would 
lead to the presence of false positives PCR bands. A positive control was also 
prepared containing a DWNN cDNA and was expected to generate long-form 
DWNN PCR product.  
 
2.14 Sequencing of DNA 
Sequencing was done using the ABI PRISM 310 Genetic Analyser (Applied 
Biosystem). The samples to be sequenced were prepared as follows: 
 
a) PCR Chain- termination based cyclic reactions 
The reaction included 4ml of terminator ready reaction mixture, 4ml of 2.5 x 
sequencing buffer, 100ng/ml of DNA to be sequenced, 4ml of primer DNA and 4ml of 
dH2O. 0.2ml tubes were used for cycling reaction. The cycling conditions used were: 
 
960C for 10sec 
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500C for 5sec          25 cycles 
600C for 4min 
 
b) Precipitation of DNA 
The cycled samples were transferred into 1.5ml microcentrifuge tubes. 16ml of dH2O 
and 64ml of non-denatured 95% ethanol were added into each PCR sample. The 
samples were vortexed briefly. The tubes were then incubated at room temperature 
for 15min. The tubes were then centrifuged at room temperature for 20min at 13 
000rpm and the orientation of the tubes were marked in order to know where the 
pellets are. The supernatant was carefully removed using a new pipette tip. 250ml of 
70% ethanol was added and the tubes were vortexed briefly, this wash step was done 
twice. The tubes were centrifuged for 10min at 13 000rpm, again marking the 
orientations of the tubes. The supernatant was carefully removed. The samples were 
dried for 15-30min at 370C. 
 
The pellets were re-suspended in template suppressor reagent and incubated at 960C 
for 5min. The samples were then loaded in the sequencing machine and sequenced. 
 
2.15 SDS-polyacrylamide gel electrophoresis (SDS-PAGE) of proteins  
Proteins were separated by denaturating them in discontinuous SDS-polyacrylamide 
gel electrophoresis, under reducing conditions. All gels were constructed from a 40% 
commercial Bis-acrylamide solution. The resolving/separating gel consisted of 12% 
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acrylamide, 0.375M Tris-Cl pH 8.8, 0.1% SDS, 0.1 APS, 0.04% TEMED. The 
stacking gel was made on top of the resolving gel and consisted of 5% acrylamide, 
0.125M Tris-Cl pH 6.8, 0.1% SDS, 0.1% APS, 0.05% TEMED. 
 
The 2x protein loading buffer was added at 50% of the final sample vo lume. Samples 
were boiled for 5min and vortexed thoroughly before loading. Gels were run at a 
constant 200V for 45min to 60min. Gels were stained in the staining solution and de-
staining was achieved by multiple washes with destaining solution. Gels were 
incubated in the drying solution for 10min. Gels were dried onto a filter paper under 
vacuum for 2hr at 800C. 
 
2.16 Expression screening of transformants 
This was prepared by inoculation of E. coli transformant colonies into 0.5ml LB with 
100mg/ml ampicillin and 0.3% glucose to improve growth as this experiment was set 
up in 1.5ml centrifuge tubes. The tubes were incubated shaking at 370C for 4 hrs. 3ml 
of 0.1M IPTG was added to the tubes and were incubated for further 2hrs. The cells 
were centrifuged and the supernatant was discarded from each tube. 0.5ml PBS was 
used to re-suspend the cells. 15ml of cell suspension and 5ml gel dye were added and 
heated at 800C for 5min and were analysed on SDS/PAGE. 
 
2.17 Recombinant production of 3C protease 
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pGEX-3C protease construct was transformed into E.coli BL 21 Gold competent cells 
and plated onto ampicillin LB plates. One colony was inoculated into 100ml LB with 
100mg/ml ampicillin and incubated at 370C o/n. The o/n culture was transferred into 
900ml ampicillin LB and the culture was grown at 370C until OD550 reached 0.6. The 
final concentration of 0.3mM IPTG was added and the culture was induced at 250C 
o/n. The cells were centrifuged at 5000rpm for 10min at 40C and the supernatant was 
discarded. The pellet was re-suspended in 10ml PBS and lysed using a freeze-thaw 
method. The cell extract was clarified at 40C for 30min at 10 000rpm. The GST-3C 
protease fusion was purified on glutathione 4B column. The GST column was 
prepared by washing with 5 column volumes (CV’s) of dH2O and equilibrated with 5 
CV’s of PBS. The protein sample was loaded on the column (the flow through was 
kept). The column was washed with 5 CV’s of PBS to remove unbound proteins. The 
bound GST-3C protease fusion protein was eluted with 15mM glutathione in 50mM 
Tris-Cl pH 8. The expression and purification was analysed on 12% SDS gel, shown 
in Fig. 4.2 and was successful. 100ml aliquots of 3C protease in PBS were prepared 
and kept at –200C. 
 
2.18 Expression and purification of recombinant DWNN  
2.18.1 Expression and purification of GST-long-form DWNN (Section 3.4)  
A single colony from the transformation plate was inoculated in 100ml LB with 
100mg/ml ampicillin and incubated at 370C o/n. The o/n culture was transferred into 
900ml LB with ampicillin and the culture was grown at 370C until OD600 reached 0.6. 
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IPTG was added to a final concentration of 0.3mM in a litre culture to induce 
expression of the fusion protein and the culture was incubated at room temperature 
o/n. The culture was centrifuged at 5 000rpm for 10min at 40C and the pellet was re-
suspended in 10ml TTBS containing 2mM PMSF to inhibit bacterial proteases. 
Working on ice, the re-suspended pellet was sonicated using 5 bursts of 30sec each, 
to lyse the cells. The sonicated sample was then centrifuged at 10 000rpm for 30min 
at 40C to precipitate cell membranes and insoluble proteins. 100ml of the clarified 
extract was kept for analysis on SDS-PAGE gel.  
 
The clarified extract was purified on a glutathione sepharose 4B column using a 
BIORAD Econo low-pressure pump. After loading, the column was washed with 
5CVs of TTBS to remove unbound proteins. The bound fusion protein was eluted 
from the column with 15mM glutathione in TBS and collected in 1ml fractions using 
BIORAD fraction collector.  
2.18.2 Expression and purification of GST-long-form DWNN (Section 4.2) 
5ml o/n cultures of positive transformants were prepared and transferred into 45ml 
LB containing 100mg/ml ampicillin. Cultures were incubated at 370C until OD550 
reached 0.5 and were then induced with 0.3mM IPTG for 4hrs at 250C. The induced 
cells were centrifuged at 5 000rpm for 10min after which pellets were re-suspended 
in 2ml PBS and sonicated in bursts of 30 seconds five times. 
Two BIORAD polyprepR columns containing 1ml of Glutathione sepharose 4B beads 
each were prepared, washed with 5CV’s of dH2O and equilibrated with 5CV’s of 
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PBS. Each sample was loaded onto each column, and washed with 4CV’s of PBS to 
remove non-specifically bound proteins. The fusion protein was eluted with 10mM 
glutathione in 50mM Tris pH 8 and 2ml fractions were collected and analysed on 
12% SDS-PAGE gel. 
2.18.3 Expression and purification of GST-short-form DWNN  
A single colony was selected and inoculated into 200ml LB containing 100mg/ml 
ampicillin and incubated at 370C o/n. The o/n culture was transferred into 1800ml of 
LB with ampicillin and incubated at 370C until OD550 reached 0.6. The cells were 
then induced with 0.3mM IPTG at 250C o/n. The 2000ml culture was centrifuged at 5 
000rpm for 10min at 40C to pellet the cells and the pellet was re-suspended in 20ml 
of PBS. The cells were lysed using the freeze-thaw method to release the proteins. 
Freeze-thaw method includes incubation of sample at –700C for 5min and then at 
370C for 5min (repeating this cycle three times). The crude extract was centrifuged at 
10 000rpm for 30min to clarify the extract for purification on a GSH column. The 
glutathione sepharose 4B column was packed and equilibrated with 5CV’s of PBS. 
The clarified extract was loaded onto the column and the column was washed with 
5CV of PBS. The bound fusion protein was eluted in a volume of 10ml using 15mM 
glutathione in 50mM Tris-Cl pH 8. 200ml of the eluate was kept at 40C for analysis.  
2.19 Lyophilisation of a protein sample 
Protein sample (~ 1ml) was transferred into a 15ml tube, used liquid Nitrogen to 
freeze the sample, uncapped the tube and freeze-dried o/n. 
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CHAPTER 3 
Recombinant expression of the long-form human DWNN domain in E.coli. 
 
3.1 Introduction 
This chapter and the next two chapters describe the recombinant expression of two 
forms of the human DWNN domain. Amplification of the DWNN gene from DWNN 
cDNA using PCR, cloning of the PCR product into pGEX vectors, expression in E. 
coli and subsequently purification of recombinant proteins are presented in detail. 
The aim of this study was to express high levels of the DWNN domain in order to 
produce concentrated samples for Nuclear Magnetic Resonance studies. Human 
DWNN cDNA was used as a template for amplification of all human DWNN 
fragments. 
 
Long-form DWNN consists of the consensus DWNN sequence (81 amino acids) and 
a 37 amino acid tail (see Fig. 3.1). Full- length DWNN is also termed “long-form 
DWNN” in this presentation. cDNA corresponding to the human DWNN domain was 
ordered from ATCC (Rockville, USA) and its sequence is shown in Appendix A. 
 
3.2 PCR amplification of the coding region for human long-form DWNN  
Forward and reverse primers for the amplification of the coding region for the human 
DWNN domain were designed and synthesised, as shown in Fig. 3.2 and Fig. 3.3 
respectively. The forward primer covered the eukaryotic transcription initiation 
sequences (AUG) and a Bam HI restriction site for cloning was introduced. Six bases 
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before a Bam HI site were incorporated to allow efficient restriction digest of the 
PCR product. The complementary region of the primer consisted of 24 base pairs. 
The reverse primer was designed such that it included Xho I restriction site for 
cloning and two stop codons (UAA and UGA) to ensure that the translation of the 
fusion protein ends in the required region. Six bases were also introduced in this 
primer prior to Xho I site. The coding region for long-form DWNN was successfully 
amplified by PCR using Takara Taq polymerase as described in Section 2.12 and the 
results are shown in Fig. 3.4.  
 
3.3 Insertion of long-form DWNN PCR product into pGEX-4T-3 vector  
The PCR product of the long-form DWNN was cloned into the pGEX-4T-3 
expression vector as described in Sections 2.10 The ligation results show that 11 
colonies were present in one plate and 13 colonies in another plate, as two plates were 
prepared for the transformation of the ligation reaction. 12 colonies from the liga tion 
plates were used to screen for the presence of transformants using colony PCR 
following the protocol in Section 2.13). 
 
The engineered primers were used in colony PCR and thus the expected product 
would be equal to the size of PCR product (384bp). The results of the colony PCR are 
shown in Fig. 3.5. The absence of a negative control PCR band in Lane 2 indicated 
that there was no contamination and presence of the PCR band at 380bp in Lane 3 
showed that the PCR worked. The presence of one positive transformant in Lane 11 
indicated the possibility that the expression construct was generated successfully. 
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A plasmid DNA from a colony that contained a positive transformant was extracted 
using the CsCl2 gradient large-scale DNA purification method and digested with Bam 
HI and Xho I to verify the presence of the insert from the transformant. The results 
were visualised on 1% agarose gel (see Fig. 3.6). The presence of a 370 bp band of 
insert and that of the vector at 4.9kb indicated that, DWNN-pGEX-4T-3 construct 
was successfully generated.  
 
The pGEX-4T-3-long-form DWNN construct was sequenced using the engineered 
forward and reverse primers (Fig. 3.2 and Fig. 3.3 respectively) on the ABI PRISM 
310 Genetic Analyser (Applied Biosystems), to determine if any mutations had 
occurred that would lead to the truncation of the expressed fusion protein. The 
sequence alignment of the sequenced DWNN (using forward primer) (Query) against 
the expected pGEX-6P-2 – long-form DWNN construct (APPENDIX B) is shown in 
Fig. 3.7, indicating that the alignment starts from base 35 of the DWNN sequence as 
the first few bases of the DWNN sequence form part of the primer-binding region. 
The Xho I site is visible at base 357-362 of the Query sequence. Fig. 3.8 shows the 
alignment of the DWNN sequence (produced by the reverse primer) with the 
expected pGEX-6P-2 – long-form DWNN construct. The sequence alignment shows 
that the entire sequence of the construct generated has no mutations because the first 
35 bases of DWNN sequence that were absent from the sequence generated by the 
forward primer are included in the sequence generated by the reverse primer. The 
third base of the query sequence mismatched with the base of the expected sequence 
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because the base-caller cannot read accurately at the beginning or at the end of the 
sequence.  
 
3.4 Expression and purification of GST-long-form DWNN fusion protein 
Human DWNN - pGEX-4T-3 construct was transformed into competent E.coli. BL 
21 (expression host strain) cells. pGEX-4T-3 vector is a GST gene fusion vector that 
has a thrombin recognition site for cleaving the target protein from the fusion protein. 
GST-fusion protein could be purified from the cell lysate by affinity chromatography 
using glutathione sepharose 4B column. The size of GST subunit is 26kDa and the 
size of the DWNN is 13kDa and thus the expected subunit size of the fusion protein 
is 39kDa. The long-form human DWNN was expressed and purified as described in 
Section 2.18.1. A280 of the elution fractions were determined to investigate fractions 
that contained the fusion protein. The graph of fraction number v/s A280 was plotted 
and is shown in Fig. 3.9. It can be concluded from the results that most of the fusion 
protein was eluted on fractions 14 – 21. These eight fractions were pooled and were 
analysed on SDS/PAGE gel, as shown in Fig. 3.10. The results show that the long-
form DWNN is highly expressed in E. coli as seen in Lane 2 and was purified 
successfully as shown in Lane 3. The purified protein in Lane 2 appears diffuse, 
which could suggest possible heterogeneity in the sample. 
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3.5 The cleavage of the fusion protein by thrombin and purification of 
DWNN 
pGEX-4T-3 expression vector incorporates a thrombin cleavage site between the 
GST and the target protein. Thrombin (Sigma) from the  human plasma was used in 
this study. Half of the pooled purified fusion protein (4ml) was digested with 10 units 
of thrombin at 370C o/n and the results were visualised on 12% SDS/PAGE gel (see 
Fig. 3.11). The expected subunit size of long-form DWNN was 13kDa and that of 
GST was 26kDa but the results reveal that the digested sample had three bands of 
sizes, 39kDa, 26kDa and 13kDa. These three bands corresponded to the fusion 
protein, GST and long-form DWNN respectvely. The presence of the fusion protein 
in the digestion sample indicated that the fusion protein was not digested to 
completion. 
 
The partially cleaved, DWNN fusion sample was dialysed against TBS at 40C o/n to 
remove glutathione from the sample which prevents binding of GST to the GST 
column. After dialysis the sample was loaded on the glutathione agarose column, 
where DWNN was collected as the flow through. GST and GST-fusion bound on the 
column were eluted using 15mM glutathione in TBS. The samples were analysed on 
12% SDS/PAGE gel, illustrated in Fig. 3.12, and the results show that the long-form 
DWNN domain was purified successfully from the GST and the fusion protein..  
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3.6 Mass spectrometric analysis of long-form DWNN 
Fig. 3.13 shows MALDI-TOF analysis of a sample of undigested fusion protein. The 
expected size of GST-long-form DWNN fusion protein was 39kDa. The peak at 
37kDa corresponds to the fusion protein. The peak at approximately 18kDa is a 
common occurrence in MALDI-TOF mass spectrometry; it is the result of the fusion 
molecules having acquired two units of charge during the ionisation phase rather than 
one, and which consequently appear with a mass/charge ratio of 37.5/2 which is ~ 
18.8kDa. 
 
The presence of smaller peaks at ~ 10kDa (corresponding to DWNN) and 26kDa 
(corresponding to GST) is an indication that cleavage of the fusion protein took place 
between GST and DWNN in the absence of thrombin. Whether it happened in vivo or 
in vitro is not clear. Furthermore the presence of the DWNN fragments in a GST-
affinity purified sample means either that proteolysis took place after elution of the 
fusion protein from the glutathione column, or else that the cleaved DWNN domain 
co-elutes with either the GST or the fusion protein. 
 
Purified DWNN was digested from fusion protein by thrombin and isolated to 
prepare for MALDI-TOF mass spectrometry. The expected sequence is shown in Fig. 
3.1. 
 
There are two extra amino acids from the GST that are included in the DWNN after 
cleavage with thrombin and these two amino acids are G and S.  The molecular 
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weight of the protein was found using the on- line server which forms part of the 
ExPASy suite of proteomics tools (URL: www.expasy.org) and found to be 13 
535.69Da. 
 
DWNN was subjected to MALDI-TOF mass spectrometry analysis using the facility 
at the Department of Molecular and Cell Biology, UCT. The results are presented in 
Fig. 3.14. These results show that long-form DWNN was shorter than expected with 
a MW of approximately ~10kDa. This suggested that DWNN had been proteolysed 
and was suspected that the proteolysis had taken place in the hydrophobic tail region, 
which is expected to be un-structured and therefore exposed to proteolysis. It was 
also suspected that thrombin played part in the unspecific cleavage of DWNN. 
 
3.7 Optimisation of thrombin cleavage 
Optimisation of conditions for thrombin cleavage was required as initial efficiency 
was  approximately 60%. The potential factors considered were the components of 
the cleavage buffer and the possibility that the steric hindrance between the GST and 
the DWNN domain was suspected on preventing the thrombin molecule from gaining 
entry to the cleavage site. To test the buffer conditions; four 100ml thrombin digests 
were prepared, each containing the purified fusion protein and 10 units of thrombin in 
TBS, with CaCl2 to a final concentration of 2.5mM. In addition, 0.5mM DTT was 
added to digest 2, 0.01% SDS was added to digest 3 and 0.5mM DTT and 0.01% 
SDS were added to digest 4. In all these digests, the amount of fusion protein in TBS 
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added was ~100ml. The digests were incubated o/n at room temperature and then 
analysed on a 12% SDS/PAGE gel, as shown in Fig 3.15. 
 
It has been observed in Fig. 3.15, that Lane 3 (digest 1) contains three main bands in 
the region ~ 13kDa, which are clearly alternative forms of the DWNN domain. The 
question arose as to whether these were N- or C- terminal digestions and whether 
these were the result of bacterial proteases, either pre or post lysis, non-specific 
cleavage by thrombin or C-terminal truncations during transcription. The tightness of 
the GST band and the diffuse nature of the uncut fusion in lane 2 suggest that there 
were variant C-terminal forms. This came as no surprise since this was expected 
because the last 37 amino acids of the protein were known to be un-structured and 
thus vulnerable to bacterial proteases. It was suspected that the largest band of 
DWNN (13kDa) corresponded to the complete DWNN domain, and the smallest to a 
complete removal of the 37 amino acid tail.  
 
Lane 4 shows a similar pattern as Lane 3, from which it was deduced that DTT had 
little effect on the digestion. DTT might be expected to lead to increased proteolysis 
of proteins stabilised by disulphide bonds, which are reduced by DTT; the absence of 
any effect comes as no surprise since DWNN was not expected to be stabilised by 
disulphide bridges. Lanes 5 and 6 show a number of new bands, indicating that the 
unfolding effect of the SDS had exposed new sites to proteolysis by thrombin. The 
band below that of GST represents proteolysis at a site in the GST sequence, 
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indicating that 0.01% SDS was sufficient to unfold GST enough for thrombin to 
cleave it internally. The three DWNN bands in lane 3 and 4 had been proteolysed 
down to a ~ 9kDa band. This is consistent with a model of a partially un-structured 
C-terminal tail, which becomes totally un-structured in the presence of SDS, allowing 
complete removal of the tail. The absence of a band at ~39kDa (fusion protein) in 
Lane 3-6, showed that thrombin digestion was efficient. This is presumably due to the 
addition of 2.5mM CaCl2 that play a role in the activity of thrombin.  
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CHAPTER 4 
Recombinant expression of the long-form human DWNN using pGEX-6P-2 
vector 
 
4.1 Insertion  of the coding region for long-form DWNN into the pGEX-6P-2 
vector 
The pGEX-4T-3 expression vector was replaced by pGEX-6P-2 expression vector for 
expression of long-form DWNN, due to the problems experienced with thrombin 
cleavage of the fusion protein. The pGEX-6P-2 vector contains a recognition site for 
the 3C protease at the immediate N-terminal to the target protein for removal of the 
GST domain. 3C protease has a higher site-specificity than thrombin (Walker et al., 
1994). 
 
The DWNN construct produced in Section 3.2 was digested with Bam HI and Xho I ( 
from New England Biolabs) and inserted into pGEX-6P-2 expression vector, which 
had been digested with the same enzymes, using the protocol described in Section 
2.9.1 Shrimp alkaline phosphatase (SAP) was included in the digestion of the vector 
in order to remove phosphate groups at the end of singly digested vector fragments to 
prevent re-circularisation of vector, which leads to high background in transformation 
plates. The digestion sample was loaded on a QIAprep spin column from QIAGEN to 
purify the digested vector DNA. The ligation reactions were prepared as shown in 
Table 2.2. 
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The ligation samples were transformed into E.coli MC1061. The results were 
recorded based on the number of colonies on the LB plates. In sample 1 plate 
(background control in which no vector was added in the ligation mixture) only 5 
colonies were observed and the colonies in this reaction resulted either from 
undigested vector or re-circularisation of singly cut vector. The number of colonies in 
ligation reaction samples 2, 3 and 4 were 11, 4 and 8 respectively thus showing that 
the number of colonies in the ligation reaction samples were greater than the number 
of colonies in sample 1, indicating that there was a high probability that some of the 
colonies in samples 2-4 contained inserts. 
 
8 colonies from sample 4 of the ligation reaction were screened for protein expression 
as described in Section 2.16. A positive control transformant containing the long-
form DWNN - pGEX-4T-3 construct and a negative control transformant pGEX 
vector were included in the experiment. The clarified extract samples were visualised 
on a 12% SDS/PAGE gel. The 39kDa band visible in Lane 2 (positive control) 
corresponds to the fusion protein. The 26kDa band in Lane 3 (negative control) 
corresponds to GST subunit. A band at 39kDa corresponding to the fusion protein is 
visible in lanes 6, 7 and 11, indicating that the desired construct were present in these 
transformants. In Lane 4, a band corresponding to GST (26kDa) is visible, indicating, 
that the ligation was unsuccessful in this transformant. 
 
4.2 Large-scale expression and purification of long-form DWNN  
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Plasmid DNA was extracted from the E. coli transformant colonies resulting from 
transformations above. The plasmid DNA was then transformed into competent 
E.coli BL21 expression host cells. Large-scale expression and purification of long-
form DWNN was prepared according to a protocol in Section 2.18.2. 500ml of the 
eluted protein was digested o/n at 40C with 20ml of non-commercial 3C protease (its 
expression and purification is described in Section 2.17 and shown in Fig. 4.2). 9mM 
EDTA was added for 3C protease activity because this protease is inhibited by Zn 
ions at 10mM and thus EDTA chelates those ions ensuring that 3C protease activity 
is optimal. Digests were visualised on a 12% SDS/PAGE gel, which is shown in Fig. 
4.3. It is evident from Fig. 4.3, that the fusion protein was successfully purified 
(Lanes 2 and 4) and cleaved to completion by 3C protease (Lanes 3 and 5) through 
the presence of a 26kDa protein band that represents GST and double bands smaller 
than 14kDa representing DWNN. The cleaved DWNN was in the form of a doublet, 
one of approximately 13kDa and one of approximately 10kDa. These results led to 
the conclusion that proteolysis of the tail region of DWNN occurred. 
 
4.3 Sequencing of the pGEX-6P-2 - long-form DWNN construct 
To determine if the expression construct had been correctly assembled, it was 
sequenced using the original PCR primers shown in Fig. 3.2 and 3.3. An alignment of 
the sequence generated using the forward primer (Query), with the expected pGEX-
6P-2 – long-form DWNN construct sequence (Sbjct) (see Appendix C). Bases 1-51 
(corresponding to DWNN sequence) were not present in the sequenced construct 
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because they formed part of the primer-binding region. The rest of the sequence 
matched the expected sequence exactly; indicating that the construct contained no 
mutations, see Fig. 4.4. The sequencing covered the Xho I site which is in base 329-
334 of the Query sequence, and the two engineered stop codons. The corresponding 
alignment of the sequence generated using the reverse primer, which is shown in Fig. 
4.5, shows that the entire sequence (1-364) is correct.  
 
4.4 Mass spectrometric analysis of long-form DWNN 
The cleaved fusion protein was dialysed against PBS to remove free glutathione and 
loaded onto a glutathione agarose column. GST was retained on the column, allowing 
DWNN to flow through. Purified DWNN fractions were pooled and analysed by 
MALDI-TOF mass spectrometry. 
 
Figures 4.6 and 4.7 show mass spectrograms of two different samples, both prepared 
as described above. Both samples show evidence of proteolysis: in Fig. 4.6 the 
predominant species has a molecular weight of approximately 11kDa, while in Fig. 
4.7 there are two clusters of approximately 10.5kDa and 12kDa respectively. A 
magnified picture of the DWNN region from Fig. 4.6 is shown in Fig. 4.8. The 
pattern of discrete peaks separated by approximately 100kDa is consistent with a 
sample in which any two molecules differ from each other by an integral number of 
amino acids. 
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To determine what this would correspond to in the context of DWNN, the molecular 
weight of a number of C-terminal truncations of DWNN was predicted using the 
ExPASy MW server (see Fig. 3.1). In each case the additional amino acids GPLGS 
added by the pGEX-6P-2 vector were included in the calculation. Truncation after 
K81 and S82 would give rise to fragments with molecular weights of 9.5kDa and 
9.617kDa respectively, from which it was concluded that proteolysis was taking place 
in the tail region. This is perfectly consistent with the model of this region as an un-
structured tail. The absence of any peaks of molecules smaller than 9.6kDa suggests 
that the consensus region of DWNN is tightly folded and therefore resistant to 
proteolysis. The fact that proteolysis was still occurring despite the use of 3C 
protease rather than thrombin confirmed that thrombin was not responsible for the 
degradation; the most likely cause of proteolysis was due to bacterial proteases, either 
in vivo or in vitro.  
 
4.5 1D proton NMR spectrum of purified long-form DWNN 
The purified DWNN was lyophilised o/n, re-suspended in 600ml D2O and inserted 
into a 5mm NMR tube using a Pasteur pipette. The 1D proton spectrum collected on 
the 600MHz spectrometer at Stellenbosch University is shown in Fig. 4.9. The 
aliphatic peaks to the right of the water resonance (4.7ppm) are an indication that 
protein is present in the sample as it is shown in Fig. 1.5 by the 1-D proton NMR 
spectrum of ubiquitin. The fact that some of the methyl groups are shifted as far as 
0ppm is an indication that the protein is well folded. The amide region to the left of 
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the water is suppressed due to exchange of the amide protons and replacement with 
deuterons, which have no resonance in this part of the spectrum. The large peak in the 
vicinity of 3.6ppm corresponds to the Tris buffer. 
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CHAPTER 5 
Recombinant expression of the human short-form DWNN domain  
 
5.1  Insertion of the coding region for short-form DWNN into the pGEX-6P-2 
expression vector 
On the evidence of the mass spectrometric analysis shown in Fig. 4.8, it was 
concluded that the tail region (see Fig. 3.1) is un-structured and therefore sensitive to 
proteolysis. It was therefore decided to shorten the construct by removing the tail 
region after S82. The coding region was re-amplified from the cDNA using the same 
forward primer shown in Fig. 3.2; the design of the new reverse primer is described 
below. 
 
5.1.1 PCR amplification of the coding region for human short -form DWNN 
As before, the new reverse primer incorporates an Xho I site for insertion into the 
pGEX-6P-2 multiple cloning cassette, as well as a double stop codon to further 
decrease the possibility of read through. The complementary region corresponds to 
bases 413 to 433 of the cDNA sequence (Appendix A), see reverse primer sequence 
in Fig. 5.1. PCR reactions were prepared using Master Mix as described in Section 
2.12. The results are presented in Fig. 5.2. The successfully amplified product is 
shown in Lane 3; the size as estimated from the gel is consistent with the expected 
size of 273bp. The absence of any product in the negative control (Lane 2) is 
evidence that the band in Lane 3 does not result from contamination. 
  55 
5.1.2 Insertion of short -form DWNN PCR product into pGEX-6P-2 vector 
The PCR product was gene-cleaned and digested with restriction enzymes as 
described in Section 2.9. The digested short-form DWNN PCR product was ligated 
with digested pGEX-6P-2 vector as shown in Table 2.3 and described in Section 
2.10. From the transformation results of the ligation reactions in sample 1 
(representing background control), 21 colonies were observed. The colony number in 
the background control plate 1 is reasonable compared to the ligation plates of 
samples 3, 4 and 5, which had 119, 107 and 96 number of colonies respectively. 7 
colonies were present in sample 2 (insert control) ligation plate and the presence of 
colonies in this ligation plate is an indication of the template carry-over from the 
gene-cleaning procedure.  
 
8 colonies were selected from the transformation plates for the preparation of small-
scale DNA extractions and DNA samples were digested with Bam HI and Xho I to 
confirm the presence of an insert. The results were analysed on 1% agarose gel 
electrophoresis (see Fig. 5.4). The presence of bands in the region of 250bp in Lanes 
2, 5, 7 and 8 confirmed that the target gene had been successfully cloned into the 
corresponding colonies. A large-scale DNA extraction using a CsCl2 gradient was 
performed on one of the colonies, and the presence of the insert was verified by Bam 
HI and Xho I digestion, as shown in Fig. 5.5.  
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5.1.3 Expression and purification of GST-short form DWNN fusion protein 
The short-form DWNN construct was transformed into E.coli BL 21 competent cells 
and plated on LB plates with ampicillin (100mg/ml). The GST-short- form DWNN 
fusion protein was expressed and purified as described in Section 2.18.3. The fusion 
protein was then digested with 3C protease to release the short- form DWNN as 
described previously and the results are shown in Fig. 5.6. From Lane 3 it is clear that 
the fusion protein had been cleaved to completion, resulting in a band of 26kDa, 
which corresponds to GST, and one of ~ 10kDa, which corresponds to DWNN. 
 
5.2  Sequencing of the pGEX-6P-2 - short-form DWNN construct 
To determine if the pGEX-6P-2 construct contained the correctly shortened form of 
DWNN, DNA was sequenced using the pGEX 5’ (forward) primer ( Appendix E) on 
the ABI PRISM 310 Genetic Analyser (Applied Biosystems). The full sequence 
alignment of the sequence generated using the pGEX 5’ primer (Query) against the 
expected pGEX-6P-2 – DWNN construct (Sbjct) (see Appendix D) is shown in Fig. 
5.7. The sequencing data confirmed that the construct contained no mutations and 
was in the correct reading frame. The pGEX 5’ primer-binding site is not close to the 
MCS of the pGEX vector and that is why the full sequence of the construct was 
attained during sequencing. 
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5.3 Reverse-phase purification of short-form DWNN 
Separation of the DWNN domain from GST after cleavage had previously been 
achieved passively by removal of the GST using a glutathione agarose column 
following the protocol in Section 4.2 . Various methods were attempted to purify the 
DWNN domain more directly, including anion and cation exchange chromatography 
at a range of different pH’s, hydrophobic interaction chromatography and reverse-
phase chromatography. All except reverse-phase were unsuccessful, with DWNN 
eluting from the column without being retained. DWNN was successfully retained by 
an anionic exchange media (POROS 20HQ from PerSeptive Biosystems) at pH 11. 
However it was not clear whether this was due to specific ion-exchange interactions 
or simply that the protein was becoming denatured, and so this method was not 
pursued. 
 
Reverse-phase chromatography is a technique that separates molecules according to 
hydrophobicity (Boyer, 1992). Hydrophobic proteins are retained on a hydrophobic 
solid phase in the presence of a polar mobile phase, but are selectively eluted as the 
polarity of the mobile phase is reduced. In this case the mobile phase was water, and 
the polarity was reduced using an increasing gradient of acetonitrile (ACN). The 
reverse phase media was 20RS POROS, which has similar characteristics to C18 
media and is thus highly hydrophobic. The medium was packed into a 1.6 ml column 
and the mobile phase was pumped at a rate of 15ml/min using a BioCAD Sprint 
Perfusion Chromatography System (PerSeptive Biosystems). The protein sample was 
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loaded in 100% Buffer A (5% ACN, 0.1% TFA, pH 2) and then eluted with a 
gradient of 0 – 60% Buffer B (95% ACN, 0.087% TFA, pH 2).  
 
The chromatogram is shown in Fig. 5.8. Three major peaks can be identified; the first 
corresponds the protein that eluted from the column without being retained, while the 
second and the third were retained by the matrix and successively eluted. 20ml 
samples from each peak were analysed on a 12% SDS/PAGE gel, which is shown in 
Fig. 5.9. The gel shows that the second peak corresponds to DWNN, and the third to 
GST and 3C protease. Suprisingly, DWNN appeared as a doublet of bands in the 
vicinity of ~ 14kDa, with additional bands running between 21 and 31kDa (marked 
“A”). The additional bands were interpreted as being due to multimerisation, possibly 
due to disulphide bridges involving Cysteine residues (short- form DWNN contains 
three Cysteine residues). This is possible because the buffer contained no DTT. With 
the addition of 10mM DTT the high molecular weight bands were no longer 
observed. 
 
5.4 Short-form DWNN MALDI-TOF mass spectrometry results 
The purified DWNN domain was analysed by MALDI-TOF mass spectrometry to 
confirm its size. The expected molecular weight of short- form DWNN, as determined 
by ExPASy MW server, is 9.6kDa. The results are shown in Fig. 5.10. The two major 
peaks correspond to 9.8 and 10.1kDa respectively. While these are a little la rger than 
expected, it was confirmed that the un-structured tail region has been successfully 
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removed through sequencing. Possible explanations for the slightly larger size of the 
molecule include cleavage by 3C upstream its expected cleavage site, or the addition 
of small-molecule adducts to the protein.  
 
5.5 1D NMR results of purified short -form DWNN 
Short-form DWNN sample was dialysed against 50mM Tris-Cl, pH 8 and then 
concentrated to the final volume of 500ml with concentration of ~ 0.5mM. 1D NMR 
data of purified short- form DWNN was collected using the 600MHz Varian 
spectrometer in the Chemistry Department of Stellenbosch University. The results are 
shown in Fig. 5.11. The ratio of signal to noise was low due to the low concentration 
of DWNN protein and the fact that the probe used was not optimised for protein 
work. However the amide peaks are visible to the left of water, aliphatics to the right 
and characteristic methyls in the vicinity of 0ppm. The spectrum confirms that the 
short- form DWNN domain is folded. 
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CHAPTER 6 
Discussion and conclusion 
 
6.1 DWNN expression constructs 
The coding regions for the two forms of DWNN domains have been inserted into two 
different types of pGEX vectors, pGEX-6P-2 and pGEX-4T-3, to produce expression 
constructs. Both vectors are components of the GST expression system and differ 
only in the type of protease recognition site they incorporate.  
 
6.1.1 pGEX-4T-3 - long-form DWNN construct 
The first expression construct was generated by cloning the full- length DWNN 
domain into pGEX-4T-3 vector, which has a thrombin recognition site. pGEX-4T-3 
expression vector was selected because after thrombin cleavage of the fusion protein, 
no extra amino acids (from the GST) were included in the target protein (see 
Appendix B). The full- length DWNN domain, which is also designated “long-form 
DWNN”, is 118 amino acids long with a MW of approximately 13kDa. The amino 
acid sequence is shown in Fig. 3.1. The construct was successfully prepared. 
Expression and purification of the fusion protein was also successful but thrombin 
did not digest the fusion protein efficiently as it is evident from Fig. 3.11.  
 
A number of experiments were done in order to improve the efficiency with which 
thrombin cleaved the fusion protein. These included the addition of denaturation 
agents in order to expose the thrombin cleavage site of the fusion protein. 0.01% SDS 
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and 0.5mM DTT were added as components of the cleavage buffer. It was observed 
that DTT had little effect on digestion while 0.01% SDS increased the efficiency of 
digestion to almost 100%. DWNN appears in a number of bands, the smallest of 
which is approximately 9kDa, which is the size of the domain after the removal of the 
tail region. These findings led to the understanding that these denaturation agents, 
especially SDS, led to the total unstructuring of the C-terminal tail of DWNN thus 
allowing proteolysis and subsequently the removal of the un-structured tail. The 
absence of any major bands less than 9kDa in size suggested that the consensus 
region of DWNN is resistant to proteolysis by thrombin even in the presence of 
0.01%SDS. 
 
These conclusions were confirmed by mass spectrometry, which showed that the 
fusion protein was approximately 2kDa smaller than expected, and cleaved DWNN 
domain was smaller than the expected by the same amount. The conclusion that was 
drawn was that the protein, DWNN domain was being non-specifically proteolysed in 
the C-terminal tail. 
 
6.1.2 pGEX-6P-2 – long-form DWNN construct 
Due to the problems encountered with thrombin cleavage, the pGEX-4T-3 vector was 
replaced with the pGEX-6P-2 expression vector, which contains a 3C protease 
recognition site. 3C protease has a longer recognition sequence and therefore a higher 
site-specificity than thrombin (Walker et al., 1994). 
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Long-form DWNN coding region was successfully inserted into pGEX-6P-2 and the 
fusion protein expressed at high levels. 3C protease digested the fusion protein to 
completion. 
 
The long-form DWNN was analysed by MALDI-TOF mass spectrometry, which 
confirmed that the expressed long-form DWNN was still subject to proteolysis. This 
was shown by the presence of peaks at the range of 10 – 11kDa in the spectrogram 
when the expected size of long-form DWNN was 13kDa. The absence of peaks 
smaller that 9.6kDa (see Fig. 4.6 – 4.8), which is the expected size of DWNN 
excluding the C-terminal, hydrophobic tail, suggested that the consensus region of 
DWNN was tightly folded and thus resistant to proteolysis. The fact that proteolysis 
was still taking place despite the use of 3C protease rather than thrombin suggested 
that thrombin had not been the main cause of proteolysis of the pGEX-4T-3 
construct. 
 
1D proton NMR data of purified DWNN was collected on the 600MHz spectrometer 
at Stellenbosch University. The data (see Fig. 4.9) showed that the protein was well 
folded, and that the buffers used were therefore suitable for large-scale purification 
for structure determination. 
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6.1.3 pGEX-6P-2 - Short-form DWNN construct 
Because of the problems encountered with proteolysis of the C-terminal tail region, it 
was decided to remove it. The coding region for a shortened form of the domain was 
amplified using PCR and inserted into the pGEX-6P-2 vector. 
 
The shortened domain was successfully expressed, purified and cleaved to 
completion with 3C protease. It was successfully separated from GST and 3C 
protease using two different methods: (i) reverse-phase chromatography and (ii) 
glutathione affinity chromatography to remove the GST and 3C protease, which is 
also a fusion with GST. Efforts to develop an ion exchange purification protocol were 
unsuccessful.  Both purification methods yielded highly purified protein, as can be 
seen from Fig 5.8 and 5.9.  
 
It was noticed that under certain conditions the purified DWNN was at a higher 
molecular weight on SDS-PAGE gels than expected (see Fig. 5.9). The higher 
molecular weight bands were interpreted as being due to disulphide bridges involving 
three cysteine residues present in short-form DWNN. This was possible because the 
buffer contained no DTT; addition of 10 mM DTT led to the removal of the high 
MW bands. 
 
The purified short- form DWNN domain was analysed by MALDI-TOF mass 
spectrometry to confirm its size. The expected MW of short- form DWNN, as 
determined by ExPASy MW server, was 9.6kDa. The results are shown in Fig. 5.10, 
  64 
and two major peaks corresponding to 9.8 and 10.1kDa were visible. Although these 
were a little larger than expected, they confirm that the un-structured region was 
removed. The sequencing data in Fig. 5.7 also confirmed the latter. Possible 
explanations for the slightly larger size of the molecule include cleavage by 3C 
protease upstream of its cleavage site, or the addition of small-molecule adducts to 
the protein. 
 
1D proton NMR spectrometry in Fig. 5.13 confirmed that the short- form DWNN 
domain was folded. 
 
6.2 Conclusion and future prospects  
The final result of the work described in this thesis was the generation of the reagents 
and protocols necessary for the large-scale recombinant production of the DWNN 
domain for structural analysis. The DWNN domain was shown to be soluble and 
correctly folded under the buffer conditions employed. As expected, the C-terminal 
hydrophobic tail forming part of the full- length protein was unstable in the bacterial 
expression system employed, and was therefore removed.  
 
Since the work described in this thesis was completed, the expression construct has 
been taken over by a co-worker and used to produce concentrated samples of pure 
short- form DWNN. These have been used to generate high quality NMR data from 
which the structure of the domain will shortly be generated. 
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APPENDIX A 
 
Full Length cDNA sequence of Human DWNN, with translation of open reading 
frame 
 
 
    CGGGGGGTCTCTGGATTATTGTTCTGACGAACCCCTGCTTGTGGTTGGGGGGTATTTAAT 
  1 ---------+---------+---------+---------+---------+---------+ 60 
 
 
    CTGAGGCCTTAGGGTCCTTCGGTGTCTTTGAGTGTTTTGTGTGTACATATTTTGCTCTTA 
 61 ---------+---------+---------+---------+---------+---------+ 120 
 
 
    AAGTTTATAAATATACGTATATTGAGAGTGTCCACGTCTCCTCGCTGAACCTTAGGAATC 
121 ---------+---------+---------+---------+---------+---------+ 180 
 
 
              M  S  C  V  H  Y  K  F  S  S  K  L  N  Y  D  T  V   
    CCTTGGCACCATGTCCTGTGTGCATTATAAATTTTCCTCTAAACTCAACTATGATACCGT 
181 ---------+---------+---------+---------+---------+---------+ 240 
 
 
     T  F  D  G  L  H  I  S  L  C  D  L  K  K  Q  I  M  G  R  E   
    CACCTTTGATGGGCTCCACATCTCCCTCTGCGACTTAAAGAAGCAGATTATGGGGAGAGA 
241 ---------+---------+---------+---------+---------+---------+ 300 
 
 
     K  L  K  A  A  D  C  D  L  Q  I  T  N  A  Q  T  K  E  E  Y   
    GAAGCTGAAAGCTGCCGACTGCGACCTGCAGATCACCAATGCGCAGACGAAAGAAGAATA 
301 ---------+---------+---------+---------+---------+---------+ 360 
 
 
     T  D  D  N  A  L  I  P  K  N  S  S  V  I  V  R  R  I  P  I   
    TACTGATGATAATGCTCTGATTCCTAAGAATTCTTCTGTAATTGTTAGAAGAATTCCTAT 
361 ---------+---------+---------+---------+---------+---------+ 420 
 
 
     G  G  V  K  S  T  S  K  T  Y  V  I  S  R  T  E  P  A  M  A   
    TGGAGGTGTTAAATCTACAAGCAAGACATATGTTATAAGTCGAACTGAACCAGCGATGGC 
421 ---------+---------+---------+---------+---------+---------+ 480 
 
 
     T  T  K  A  V  C  K  N  T  I  S  H  F  F  Y  T  L  L  L  P   
    AACTACAAAAGCAGTATGTAAAAACACAATCTCACACTTTTTCTACACATTGCTTTTACC 
481 ---------+---------+---------+---------+---------+---------+ 540 
 
 
     L  *                                                         
    TTTATAATGTAGCAGTGAAGTAAATCATTTTAGAACTTAATATCCAACTGATCATAGTAC 
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541 ---------+---------+---------+---------+---------+---------+ 600 
 
 
    ATATTGTAAATAAAATGTATTTTGATGACAGCTCAGTTGAATATGGATAATATGTGGCAT 
601 ---------+---------+---------+---------+---------+---------+ 660 
 
 
    CACTTGCACACTTATTTTGTAGAAATGGGTAATTTGTGCCCGTAACACTGTTTCATATTA 
661 ---------+---------+---------+---------+---------+---------+ 720 
 
 
    AATATGATAGCATTATCCCTGTATGACACTGTGTTGTACAGTTAATGTATGATCCTTTTT 
721 ---------+---------+---------+---------+---------+---------+ 780 
 
 
    AGATCGTTTAGGTTTTACACTAAGGAACATGATGACATGTTCTACATTTGTCTGTCTATA 
781 ---------+---------+---------+---------+---------+---------+ 840 
 
 
    GTTAGTATTTTGTATGTATGTACAGGCTGTTGTGTGCTTTTTGTTTCTTGCAATAAAAAA 
841 ---------+---------+---------+---------+---------+---------+ 900 
 
 
    TGTTTGGAGTGTAAAAAAAAAAAAAAAAA 
901 ---------+---------+--------- 929 
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Appendix B 
 
Expected pGEX (4T-3) – DWNN (long-form) construct (Mutiple Cloning Site) 
 
 
 
   L      V      P       R       G       S       M      S      C      V       H      Y      K      F      S       
S       K      L      N      Y       D      T       V        
CTG GTT CCG CGT GGA TCC ATG TCC TGT GTG CAT TAT AAA TTT TCC 
TCT AAA CTC AAC TAT GAT ACC GTC  
   T       F       D      G      L      H       I       S       L      C       D     L       K      K       Q       
I       M      G      R       E       K       L       K       
ACC TTT GAT GGG CTC CAC ATC TCC CTC TGC GAC TTA AAG AAG CAG 
ATT ATG GGG AGA GAG AAG CTG AAA  
   A      A       D     C       D      L       Q      I       T        N      A      Q       T       K      E        
E       Y      T      D       D      N      A      L        
GCT GCC GAC TGC GAC CTG CAG ATC ACC AAT GCG CAG ACG AAA 
GAA GAA TAT ACT GAT GAT AAT GCT CTG  
    I      P       K      N      S       S      V       I       V      R       R       I      P       I       G       
G      V      K      S       T       S       K       T       
ATT CCT AAG AAT TCT TCT GTA ATT GTT AGA AGA ATT CCT ATT GGA 
GGT GTT AAA TCT ACA AGC AAG ACA  
   Y     V      I        S       R       T       E      P       A      M       A      T       T       K       A     
V       C      K      N       T       I       S       H       
TAT GTT ATA AGT CGA ACT GAA CCA GCG ATG GCA ACT ACA AAA 
GCA GTA TGT AAA AAC ACA ATC TCA CAC  
   F      F      Y       T      L       L      L       P      L       *        * 
TTT TTC TAC ACA TTG CTT TTA CCT TTA TAA TGA CTC GAG 
CGGCCGCATCGTGACTGACTGA 
 
Bam HI 
   Xho 
I 
Forward primer region 
Thrombin site 
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* Stop Codon 
  
 
 
 
 
 
Reverse primer region 
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APPENDIX C 
Expected pGEX 6P-2 – DWNN (long-form) construct (Mutiple Cloning Site) 
 
 
   L       E      V       L     F       Q       G       P       L      G       S       M      S      C      V       
H      Y      K      F      S       S       K      L       
CTG GAA GTT CTG TTC CAG GGG CCC CTG GGA TCC ATG TCC TGT GTG 
CAT TAT AAA TTT TCC TCT AAA CTC  
   N      Y      D      T       V       T      F       D      G      L      H       I       S       L      C       
D     L       K      K       Q       I       M      G       
AAC TAT GAT ACC GTC ACC TTT GAT GGG CTC CAC ATC TCC CTC TGC 
GAC TTA AAG AAG CAG ATT ATG GGG  
   R       E       K       L       K       A     A       D     C       D      L       Q      I       T        N      
A      Q       T       K      E        E       Y      T       
AGA GAG AAG CTG AAA GCT GCC GAC TGC GAC CTG CAG ATC ACC 
AAT GCG CAG ACG AAA GAA GAA TAT ACT  
   D       D      N      A      L       I       P       K      N      S       S      V       I       V      R       
R       I      P       I       G       G      V      K       
GAT GAT AAT GCT CTG ATT CCT AAG AAT TCT TCT GTA ATT GTT AGA 
AGA ATT CCT ATT GGA GGT GTT AAA  
   S       T       S       K       T     Y      V       I        S       R       T       E      P       A      M       
A      T       T      K       A      V      C      K       
TCT ACA AGC AAG ACA TAT GTT ATA AGT CGA ACT GAA CCA GCG ATG 
GCA ACT ACA AAA GCA GTA TGT AAA  
   N       T       I       S       H      F      F      Y       T      L       L      L       P      L   Stop 
codons 
AAC ACA ATC TCA CAC TTT TTC TAC ACA TTG CTT TTA CCT TTA TAA 
TGA CTC GAG CGGCCGCATCG 
Bam HI 
Xho I 
Forward primer region 
Prescission Protease 
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 Reverse primer region 
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APPENDIX D 
 
Expected pGEX 6P-2 - DWNN (short-form) construct (Mutiple Cloning Site) 
 
 
 
 
 
     L       G      V      L      F       Q       G      P       L       G       S      M      S      C      V       
H     Y       K       F      S       S      K       L  
  CTG GAA GTT CTG TTC CAG GGG CCC CTG GGA TCC ATG TCC TGT 
GTG CAT TAT AAA TTT TCC TCT AAA CTC  
   N      Y      D      T       V       T      F      D       G      L      H       I       S       L      C       
D     L       K       K      Q       I       M      G  
AAC TAT GAT ACC GTC ACC TTT GAT GGG CTC CAC ATC TCC CTC TGC 
GAC TTA AAG AAG CAG ATT ATG GGG  
    R      E      K       L       K      A      A      D      C       D      L       Q       I       T        N      
A      Q       T       K      E       E      Y       T  
GCC GAC TGC GAC CTG CAG ATC ACC AAT GCG CAG ACG AAA GAA 
GAA TAT ACT GAT GAT AAT GCT CTG ATT  
   D       D      N       A       L       I       P       K      N      S       S     V        I      V       R       
R       I       P       I       G      G      V      K       
AGA GAG AAG CTG AAA GCT CCT AAG AAT TCT TCT GTA ATT GTT AGA 
AGA ATT CCT ATT GGA GGT GTT AAA 
   S       *       * 
TCT TGA TAA CTC GAG CGG CCG CAT CG 
 
 
 
* Stop Codon 
PreScission Protease 
 
Bam HI 
Forward primer region 
Xho I 
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APPENDIX E 
 
pGEX 5’ Sequencing Primer: 
 
5’-
d[GGGCTGGCAAGCCACGTTTGGT
G]-3’ 
 
pGEX 5’Sequencing Primer Binding Site is situated at position 869-891 
of all pGEX vectors. 
 
